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SocietyThe US Food Drug Administration (FDA) developed guid-
ance describing an osteoarthritis (OA) drug development
‘‘roadmap’’, which has been in draft format since 19991.
This guidance describes a process for drug approval for
speciﬁc indications in OA, including treatment of symptoms,
delays in structural progression and even discusses
prevention of OA. At present, an alteration in structural
progression would likely be determined by x-ray, but it is
possible that newer technologies may include magnetic res-
onance imaging or even ultrasound once appropriately
validated. The indication of improvement in signs and
symptoms presently needs three co-primary outcomes to
be measured including pain, patient global assessment
and a functional measure, which at present should be the
WOMAC. These studies need to be adequate, well de-
signed and controlled. It is possible that therapies for the
treatment of the pain of OA could be approved with only
a pain measure as a primary endpoint with a functional as-
sessment and analysis of the patient global response as
secondary outcomes, each of which should not worsen
throughout the course of the clinical study.
Fundamentally, patients visit their health care provider
when they suffer symptoms such as pain or loss of function,
rather than to complain of a speciﬁc disease. In the context
of OA, patients will typically complain of pain, stiffness, or de-
creased function in one or more joints. An important longer-
term problem is that their decreased function and pain might
lead ultimately to the requirement for surgery including joint
replacement. Thus far, it has not been shown that the ther-
apies developed to improve the signs and symptoms of OA
might impact the structural progression of the disease. In
longitudinal studies, many patients with OA suffer progres-
sive joint damage. Unfortunately, not all damage has
been linked to a progressive increase in pain and/or loss
of function. However, the process is probably not linear,
and at the present time it is difﬁcult to predict progression
of joint damage. Furthermore, it is currently challenging to
predict who will become disabled and who will not. Most
patients would like to know that their symptomatic therapy
would lead to decrease in pain and an improvement in
function, as well as provide a potential beneﬁt in inhibiting
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USA. E-mail: lsimon@bidmc.harvard.eduAprogressive damage. Unfortunately, to date there has
been no therapy proposed which might beneﬁt all aspects
of OA. Importantly, if a therapy might prevent further
structural damage, it must at some point be linked to
some beneﬁcial clinical outcome. These beneﬁts might
include the decreased need for a joint replacement or a
decrease in pain and improvement in function. It is as yet
unproven that small changes measured by an imaging
modality will predict an important clinical beneﬁt. In a local-
ized process such as OA, it is important to study the joint
most symptomatic to the patient to allow for a valid under-
standing of clinical beneﬁt. Although there are patients
who only suffer disease in one joint, more typically patients
suffer from OA in at least several joints. Thus, a corollary to
the primary objective of assessing the most affected joint, is
that symptoms in joints elsewhere in the body do not
worsen.
Drugs that will do more than palliate the symptoms of OA
have been difﬁcult to develop. There remain no therapies
that have been shown to have an important effect on the
fundamental biologic processes of this disease. Unfortu-
nately, this lack of structure modifying therapies might partly
be due to the difﬁculties in measuring and documenting
such a beneﬁt. These beneﬁcial changes could potentially
be detected as differences in changes in joint space width,
measuring change in ligamentous laxity, alterations in sub-
chondral bone, development of subchondral cysts, or the
generation of osteophytes.
Any or all of these characteristics of an OA-affected knee
might sufﬁce; however, it is essential to determine how
structural changes are linked clinical beneﬁt. In terms of
OA, this linked beneﬁt could be demonstrated either before,
at the time that structural beneﬁts were determined, or even
subsequently. The suggestion therefore is that this mea-
sured structural change might serve as a surrogate beneﬁt
that can be measured earlier than the desired clinical ben-
eﬁt. A surrogate outcome is an endpoint of a clinical trial,
which might be a laboratory measurement, or a physical
sign used as a substitute for a clinically meaningful endpoint
possibly measured directly, determining how a subject
feels, functions or survives. Changes that might be induced
by a speciﬁc therapy on a surrogate endpoint would be
expected to reﬂect changes in a clinically meaningful end-
point. The ultimate clinical beneﬁt could include improve-
ment in pain, function, or delay in the need for surgical
intervention. In addition, these markers might be used as
signals of beneﬁt, help to compare therapies, identify at
risk patients and access efﬁcacy.2
A3Osteoarthritis and Cartilage Vol. 14, Supplement ATaken together, the key issues are that, since no therapy
is totally safe, we need to develop therapies with beneﬁts
that serve to outweigh the potential risks of use, especially
in the circumstance of long term use. In that modiﬁcation of
structural damage (either reversal or inhibition of further
progression) in OA is felt to be important, the observation
must be anchored to a documented clinical beneﬁt of
some type. The continued issue is to understand whether
what is to be measured by imaging (e.g. a change in jointspace width of several millimeters during the deﬁned
window of observation that a clinical trial provides) is an im-
portant and clinically relevant outcome. Without this, then
the beneﬁt to risk ratio becomes difﬁcult to ascertain.
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